Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mads Lamm Larsen1,2, Anne Voss3, Christoffer Tandrup Holst Nielsen4

  • 1Afdelingen for Led- og Bindevævssygdomme, Aarhus Universitetshospital.

Ugeskrift for Laeger
|November 22, 2024
PubMed
Summary

Chimeric antigen receptor T-cell (CAR-T) therapy shows promise for autoimmune rheumatic diseases. Early data suggest CD19 CAR-T therapy is effective and safe for severe, treatment-resistant cases.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Predictors of relapse, early escalation and 1-Year use of glucocorticoids in new-onset polymyalgia rheumatica: A prospective cohort study.

Seminars in arthritis and rheumatism·2026
Same author

Long-term risk of malignancies in ANCA-associated vasculitis.

EULAR rheumatology open·2026
Same author

Biological tapering is cost-effective in patients with inflammatory arthritis in the biosimilar era: secondary analyses on the randomised BIODOPT trial.

EULAR rheumatology open·2026
Same author

Precision Proteomic Profiling of Systemic Lupus Erythematosus-Correlating Disease Activity and Complement Levels with Clinical Phenotypes.

Biomedicines·2026
Same author

Teclistamab for treatment-refractory autoimmune diseases: a multicentre case series.

Annals of the rheumatic diseases·2026
Same author

Teclistamab induces rapid clinical response and deep tissue depletion in refractory systemic sclerosis-a case series.

Annals of the rheumatic diseases·2026

Area of Science:

  • Immunology
  • Rheumatology
  • Cellular Therapy

Background:

  • Systemic autoimmune rheumatic diseases present significant treatment challenges.
  • Novel therapeutic strategies are needed for severe, refractory cases.

Approach:

  • Review of emerging evidence on Chimeric Antigen Receptor T-cell (CAR-T) therapy in rheumatology.
  • Focus on CD19-targeted CAR-T therapy for autoimmune conditions.

Key Points:

  • CAR-T therapy is a novel approach for systemic autoimmune rheumatic diseases.
  • Current evidence, primarily from case studies, indicates rapid and highly effective responses.
  • A favorable side effect profile has been observed.

Conclusions:

Related Experiment Videos

  • CD19 CAR-T therapy holds potential for established use in rheumatology.
  • This therapy may be particularly beneficial for severe, treatment-resistant rheumatic diseases.